SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Memecoin on Cronos launched by the Cro Crow community

crow with knife

Crowd with Knife ($CAW.X) is trending due to its listing on Coinbase, sparking excitement within the community. Discussions highlight its multi-chain functionality and fully circulated supply. Community members express bullish sentiment and are actively spreading awareness.

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPY is trending amid discussions around the Fed's latest rate cut and its potential impact on the market, with Goldman Sachs maintaining its forecast for further cuts. Community members are debating market direction, with some anticipating continued upward momentum while others express concerns about overvaluation and potential pullbacks. Additionally, there's chatter about political and economic factors influencing market sentiment.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

GRRR is trending due to a newly announced $1.4 billion contract to build AI-powered data centers in Southeast Asia, sparking excitement about the company's growth potential in the AI infrastructure space. The community is actively debating the legitimacy of the contract, potential revenue impact, and overall valuation in comparison to its peers. Discussions also involve upcoming events and potential partnerships, specifically around the O.N.E. Amazon initiative.

"What's Updog?" is a Community Led token.

UpDog

UpDog ($UPDOG.X) is trending as the community rallies around the joke-inspired meme coin built on Solana, asking "What's Updog?". The community highlights its long-term presence on Solana, locked liquidity, and Jupiter Strict List inclusion. Some users are drawn to its potential for meme-driven growth, while others appreciate the project's charitable aspect.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQ is trending following news of a memorandum of understanding with the U.S. Department of Energy to advance quantum technologies in space, fueling discussions about the company's role in the future of quantum computing. The community is actively debating the long-term potential of quantum technology and whether IonQ can achieve significant revenue growth to justify its valuation, with some drawing comparisons to other high-growth tech companies.

MicroAlgo, Inc. operates as a holding company, which engages in the development and application of bespoke central processing algorithms. Its services include algorithm optimization, accelerating computing power without the need for hardware upgrades, lightweight data processing, and data intelligence. The company was founded May 14, 2018 and is headquartered in New York, NY.

MicroAlgo Inc

MicroAlgo (MLGO) is trending amid community discussion of a potential short squeeze, fueled by its small float and high short interest. Some traders are pointing to the stock's history of volatility and previous significant runs, while others highlight the company's AI, quantum, and blockchain updates as potential catalysts. Discussions also mention the company's recent financial results and the potential for sector-wide momentum.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings ($RCAT) is trending amid discussions about a potential stock offering and its implications for the stock's momentum, with some fearing a repeat of past dilutions while others see it as a necessary step for funding expansion, particularly in the maritime drone division. Community members are actively debating the size and pricing of the offering, its potential impact on the share price, and the company's overall financial management. Despite concerns, many remain bullish on $RCAT's long-term prospects, citing potential government contracts and the company's involvement with NATO.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending amid discussions about the Federal Reserve's rate cut and its potential impact on the market, with community members debating whether the move signals a sustained bull market or a potential trap. Some are pointing to technical indicators and geopolitical factors, such as Nvidia's China chip ban, as reasons for caution, while others express bullish sentiment and anticipate further gains. The conversation also includes reactions to news events, like the announcement of a deal for 89bio to be acquired by Roche.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum (QBTS) is trending as quantum computing stocks gain momentum, fueled by potential breakthroughs and real-world applications. Community members are actively discussing its valuation, revenue growth, and potential for acquisitions, along with possible government contracts. The stock is experiencing volatility as traders weigh its prospects against established players in the sector, while some express concerns over insider selling.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is trending following news of a multiyear partnership with Google to integrate payment solutions and leverage AI, sparking community excitement about potential revenue growth. While some investors are optimistic about the deal's potential and the company's buyback program, others express concern about the stock's historical performance and the magnitude of the deal's impact. The partnership arrives as the fintech sector faces increased competition and regulatory scrutiny.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wolfpack Research announced on Thursday its short position in EV maker Faraday Future (FFAI) and opined that it would likely revert to being a penny stock before eventually delisting.The firm <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.wolfpackresearch.com/items/ffai%3A-this-house-of-cards-is-falling-apart-as-yt-jia%E2%80%99s-latest-pump-is-built-on-fake-orders-and-a-tsunami-of-lies">stated</a> that it believes the latest pump in stock value was based on “fake orders, a rebadged Chinese minivan and a tsunami of lies” intended to induce retail investors to buy ahead of dilution.FFAI’s stock jumped on July 22 after Nature’s Miracle announced a preorder of 1000 EV minivans in a deal worth up to $100 million. However, Wolfpack thinks this is fake, provided that Nature’s Miracle does not have the cash to make such a purchase. Further, the founder of Nature’s Miracle and Faraday Future CEO Jia Yueting were classmates in business school, the firm noted.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/FFAI">FFAI stock</a> remained within ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.Wolfpack alleged, citing former employees and media reports, that the EV minivan called the FX Super One is a rebadged vehicle from Chinese automaker Great Wall Motors. The over 10,000 pre-orders for the vehicle are all non-binding, including the one made by Nature’s Miracle, it added.While the company recently announced $82 million of new financing, Faraday didn't reveal the financier, and Wolfpack believes this may be a reiteration of prior financing rounds where the CEO and other insiders appear to have used fronts to disguise that they were the ultimate source of funding. The firm also raised doubts about how the CEO has money to fund the company after emerging from his personal bankruptcy. “We think he hid assets from the bankruptcy court,” it said, while adding that this includes homes on the California coast and shares of Lucid.The ultimate goal of these moves by the company appears to be to pump up the stock ahead of massive dilution, Wolfpack alleged. FFAI is slated to vote on September 19 to increase the authorized common share count by 39% and issue shares to certain convertible note and warrant holders.YT Jia returned as co-CEO of the EV maker in April earlier this year after stepping down in 2019. However, Wolfpack believes this was “theater” since he was running the company even while he was not in the CEO position.FFAI stock is down 29% this year and approximately 57% over the past 12 months.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ford-supplier-magna-international-appoints-former-timken-executive-as-cfo/chwNkSJRdvj">Ford Supplier Magna International Appoints Former Timken Executive As CFO</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Faraday Future logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Wolfpack Research Reveals Short Position In EV Maker Faraday Future

The firm stated that it believes the latest pump in stock value was based on “fake orders, a rebadged Chinese minivan and a tsunami of lies” intended to induce retail investors to buy. 

Equity

The firm stated that it believes the latest pump in stock value was based on “fake orders, a rebadged Chinese minivan and a tsunami of lies” intended to induce retail investors to buy. 


Rapport Therapeutics, Inc. (RAPP) on Monday said that a mid-stage clinical trial of RAP-219 in patients with drug-resistant focal onset seizures demonstrated a statistically significant reduction in long episodes over the 8-week treatment period.RAP-219 also <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.rapportrx.com/news-releases/news-release-details/rapport-announces-positive-topline-results-phase-2a-clinical">demonstrated</a> a statistically significant and clinically meaningful reduction in seizures accompanied by physical signs compared with baseline in the study, the company said, while adding that it plans to advance the investigational therapy into two late-stage trials in the third quarter of 2026.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/RAPP">RAPP stock</a> stayed within ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels. Shares of the company traded 204% higher in the pre-market session at the time of writing.<figure class="image"><img style="aspect-ratio:575/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_08_at_8_06_25_AM_png_a5918d7983.webp" alt="RAPP's Sentiment Meter and Message Volume as of 8:15 a.m. ET on Sept. 8, 2025 | Source: Stocktwits" width="575" height="61"><figcaption>RAPP's Sentiment Meter and Message Volume as of 8:15 a.m. ET on Sept. 8, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user sounded optimistic, saying the update is ‘great news.’<stembedurl>https://stocktwits.com/Mushichka/message/627808704</stembedurl>Another user, however, expressed doubts about whether the data warrants the massive rally.<stembedurl>https://stocktwits.com/Trader_Tom/message/627805877</stembedurl>H.C. Wainwright subsequently raised its price target on Rapport to $34 from $31 while keeping a ‘Buy’ rating on the shares. The firm states that RAP-219 surpassed its "most bullish expectations" and added that the data provides "unimpeachable evidence" of the drug's effect, offering "strong evidence that it has the potential to become a mainstay" in the treatment of focal onset seizures. The firm increased its probability of success for oral RAP-219 to 66% and its peak revenue estimate to $766 million, up from $613 million.Focal onset seizures are seizures that begin in one area of one brain hemisphere, causing symptoms that typically affect one side of the body or are limited to a specific sensation, emotion, or movement. In the trial, Rapport enrolled 30 patients, 18 men and 12 women, with focal onset seizures who had an implanted RNS System, a brain simulation device for drug-resistant focal epilepsy. The patients received 0.75 mg of RAP-219 oral tablets daily for 5 days, followed by 1.25 mg of RAP-219 oral tablets daily for the remainder of the 8-week treatment period.During the treatment period, over 85% patients achieved more than or equal to 30% reduction in long episodes from baseline, the company said, while 72% achieved more than or equal to 50% reduction. Twenty-four patients also achieved seizure freedom, the company said. Reduction in long episodes (LEs) is an objective electrographic biomarker for clinical seizure reduction, it said.RAP-219 was generally well-tolerated in the trial, with the majority of treatment-emergent adverse events being mild and a low discontinuation rate, the company added.Rapport plans to hold an end-of-mid-stage trial meeting with the U.S. Food and Drug Administration (FDA) in the fourth quarter of 2025. The company also expects to present additional efficacy analyses and 8-week follow-up results in 2026 and to initiate a trial to evaluate the long-term safety of the therapy in patients by the end of 2025. RAP-219 is also being evaluated in bipolar mania and diabetic peripheral neuropathic pain.RAPP stock is down 19% this year and approximately 27% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/pnc-to-buy-colorado-first-bank-for-4-1-b-in-push-to-bolster-national-reach/chwWxbxRdrR">PNC To Buy Colorado’s FirstBank for $4.1B In Push To Bolster National Reach: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Rapport Therapeutics Stock Rockets 204% Pre-Market To Head Toward All-Time Highs – Here’s What Happened

The company said that it now plans to advance the investigational therapy into two late-stage trials in the third quarter of 2026. 

Shares of Tonix Pharmaceuticals Holding Corp. (TNXP) jumped 4% in the pre-market session on Monday after its drug Tonmya received the U.S. Food and Drug Administration’s (FDA) approval for the treatment of fibromyalgia in adults.Fibromyalgia is a chronic pain disorder that is understood to result from amplified sensory and pain signaling within the central nervous system. Fibromyalgia afflicts an estimated 10 million adults in the U.S., mostly women, and symptoms include chronic widespread pain and fatigue, among others.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.tonixpharma.com/news-events/press-releases/detail/1585/tonix-pharmaceuticals-announces-fda-approval-of">announced</a> the approval on Friday evening. Tonmya is a non-opioid, once-daily bedtime analgesic designed for rapid absorption into the bloodstream. It is also the first FDA-approved therapy for the treatment of fibromyalgia in over 15 years, Tonix said.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/TNXP">Tonix</a> trended in the ‘extremely bullish’ territory over the past 24 hours, coupled with ‘extremely high’ message volume. According to Stocktwits data, retail chatter around the stock jumped 72% over the past 24 hours and by 281% over the past seven days.<figure class="image"><img style="aspect-ratio:566/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_18_at_8_26_39_AM_png_c112eeec38.webp" alt="TNXP's Sentiment Meter and Message Volume as of 8:25 a.m. ET on Aug. 18, 2025 | Source: Stocktwits" width="566" height="62"><figcaption>TNXP's Sentiment Meter and Message Volume as of 8:25 a.m. ET on Aug. 18, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user dismissed hopes for a massive rally, adding that ‘this is a marathon not a sprint.’<stembedurl>https://stocktwits.com/AlwaysABullNeverABear/message/625581652</stembedurl>Another user said they see significant market potential for the drug.<stembedurl>https://stocktwits.com/GeneralAdam/message/625580421</stembedurl>In two late-stage trials, Tonmya significantly reduced fibromyalgia pain compared to placebo at 14 weeks. The drug was generally well-tolerated in late-stage trials, and a greater percentage of study participants taking Tonmya experienced a clinically meaningful improvement in their pain after three months, compared to placebo. Tonmya is expected to be available for adult patients in the U.S. with fibromyalgia beginning in the fourth quarter of this year.TNXP stock is up by 56% this year and by over 15% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/cryptocurrency/bitcoin-slips-under-116000-while-cardano-solana-lead-altcoin-selloff/chsO7iYRdQw">Bitcoin Slips Under $116,000 While Cardano, Solana Lead Altcoin Selloff</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Tonix Pharmaceuticals logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

This Pharma Stock Shot Up 4% Pre-Market After FDA Approval For Drug, Retail’s Super Bullish But Believes ‘This Is A Marathon, Not A Sprint’

Tonmya is the first FDA-approved therapy for the treatment of fibromyalgia in over 15 years, Tonix said. 

ProShares Trust - ProShares Ultra Russell 2000 2X Shares

Just the one

Three

Four

The Fed just cut rates. How many cuts do you expect in all of 2025? 
 
*Powered by Polymarket

UWM
ProShares Ultra Russell2000

Feed

News

Sentiment

Fundamentals

Info

Latest UWM News

UWM ProShares Ultra Russell2000